Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
Key Highlights
- ➤$8.1M committed customer orders as of October 20, up more than 300% from year-end 2025
- ➤$5.1M CDMO agreement includes analytical work, manufacturing readiness, clinical supply, and stability testing
- ➤$4M financing generated approximately $3.6M net proceeds after transaction expenses
- ➤$5.3M combined net proceeds include $1.67M from SEPA and $3.6M from completed financing
- ➤Operating runway estimated through late 2027, potentially extending into Q3 2028
Expert Statements
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Last week's CDMO agreement and completed financing materially strengthen Scinai's ability to execute its strategy.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Our new agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Our aim with these SEPA drawdowns was to raise capital during the elevated trading activity while limiting the number of ADSs issued relative to overall trading volume.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“I recognize the dilution associated with these equity financings.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Under our current operating and CDMO sales plans, our cash resources following the recent financing and expected customer payments support an estimated operating runway to late 2027.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“As the later project phases described above are activated and delivered, their cash receipts could extend that runway into the third quarter of 2028.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Our immediate priority is to turn committed work into successful customer outcomes, revenue and cash collections.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“We are also working to broaden our customer base and win additional business, including in the United States and Europe.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics Ltd.
“Our financial objective remains sustainable profitability and reduced reliance on repeated equity financing.”
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing PR Newswire
Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and delivered
Get started
Create a free account to read the full story.